Candessartan, an AT1 receptor antagonist, could reduce TGF-β1 expression and the degree of fibrosis, indicating that Ang II might promote TGF-β1 expression and aggravate the degree of pulmonary fibrosis (26). Here, AGTR1 is linked to pulmonary fibrosis.